Last reviewed · How we verify
NCT07182526
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Phase 2 trial testing Quercetin in PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries in 150 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Al-Mustansiriyah University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 20 September 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Quercetin (QUERCETIN) — full drug profile →
- Alpha Lipoic Acid 600 MG Oral Tablet — full drug profile →
- MetFORMIN 500 Mg Oral Tablet — full drug profile →
Conditions studied
- PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries — all drugs for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries →
Sponsor
Al-Mustansiriyah University
Who can join
18 and older, any sex, with PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07182526
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Quercetin
Trials testing the same drug.
- NCT07144293 — Improving Physical Ability and Cellular Senescence Elimination in HIV · Phase 2 · active not recruiting
- NCT07025226 — Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of P · EARLY_PHASE1 · recruiting
- NCT06940297 — Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07380178 — The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis · NA · completed
- NCT06650891 — Quercetin Effect on Post-ceserean Pain · Phase 3 · completed
Other recruiting trials for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Currently open trials in the same condition.
- NCT05734287 — The Frequency of Polycystic Ovary Syndrome Among Young Reproductive Females Presenting With Hyperandrogenism: a Mixed Co · recruiting
- NCT06050265 — Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome · NA · active not recruiting
- NCT05819853 — Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome · Phase 3 · recruiting
- NCT05756023 — IVF\ICSI Outcome in Women With Polycystic Ovary Syndrome · NA · recruiting
- NCT06041204 — Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism · NA · recruiting
Other Al-Mustansiriyah University trials
Trials by the same sponsor.
- NCT07375004 — Injectable PRF in Non-Surgical Periodontal Treatment · NA · active not recruiting
- NCT06921434 — the Effect of Monk Fruit and Splenda on Salivary Ph and Streptococcus Mutans Count in Vivo Study · NA · not yet recruiting
- NCT07493291 — Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients · active not recruiting
- NCT07020078 — Oral Health Condition Among a Group of Ionizing Radiation Field Workers · not yet recruiting
- NCT07133659 — Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot S · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07182526 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al-Mustansiriyah University
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07182526.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing